Do you want to read an article? Please log in or register.
Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial results
Breast Cancer
Indications
Related content
Breast Cancer
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial
JAMA Oncol
Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ
doi: 10.1001/jamaoncol.2026.2576
Breast Cancer
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial
Ann Oncol
Garber JE, Cameron D, Campbell C, Yothers G, Taboada M, El-Abed S, Rastogi P, McConnell R, Correa A, Delaloge S, Liu WT, Sharma P, Bergh J, Janni W, Balmaña J, Loman N, Španić T, Friedman S, Freeman T, Armstrong A, Korde L, Im S, Sagara Y, Viale G, Bliss J, Gianni L, Jóhannsson Ó, Zoppoli G, De Dueñas EM, Marmé F, Fein L, Arnedos M, Ford J, Schmutzler R, Loibl S, Linderholm B, Lakhani SR, Gnant M, Gelmon K, Domchek SM, Senkus E, Eisen A, Jager A, Piccart M, Phillips KA, Traina T, Stickeler E, Singer CF, Shao Z, Liu X, Tipping H, Aktan G, Martinez M, Canon JL, Takahashi M, Yasojima H, Middleton K, Pristauz-Telsnigg G, Pfeiler G, Virani S, Valdes-Albini F, Wolmark N, Mesa ID, Paterson V, Gelber RD, Geyer CE Jr, Tutt ANJ
doi: 10.1016/j.annonc.2026.08.002
Breast Cancer
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial
Ann Oncol
Dugo M, Huang CS, Egle D, Bermejo B, Seitz RS, Nielsen TJ, Zamagni C, Thill M, Antón-Torres A, Russo S, Sevillano E, Ciruelos EM, Schweitzer BL, Galbardi B, Greil R, Semiglazov V, Colleoni M, Kelly CM, Del Mastro L, Mariani G, Viale G, Győrffy B, Ali HR, Pusztai L, Viale G, Callari M, Gianni L, Bianchini G
doi: 10.1016/j.annonc.2026.05.694
Breast Cancer
A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial
Ann Oncol
Kim GM, Jung KH, Jeung HC, Lee J, Lee KS, Im SA, Kang SY, Kim SH, Kim HJ, Park KH, Chae YS, Koh SJ, Cho EK, Park KU, Lee SS, Kim JY, Choi IS, Baek SK, Moon YW, Kim SG, Lim ST, Lee KH, Kim HJ, Kim MH, Kim KH, Kim SI, Park S, Park HS, Kim JY, Kim YB, Kim SB, Ahn JH, Jeong JH, Kim JH, Jeong J, Park WC, Sim SH, Lee K, Nam CM, Park S, Paik S, Sohn J, Korean Cancer Study Group (KCSG)
doi: 10.1016/j.annonc.2026.05.703
Breast Cancer
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
J Clin Oncol
Offersen BV, Alsner J, Høgsbjerg K, Nielsen HM, Maae E, Nielsen MH, Mjaaland I, Maraldo MV, Kirkove C, Lörincz T, Al-Rawi S, Blix ES, Schreiber A, Krause M, Kasti UM, Matthiessen LW, Kronborg C, Tramm T, Jensen MB, Overgaard J, DBCG RT Committee
doi: 10.1200/JCO-25-02705
Breast Cancer
Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer
Lancet Oncol
Kaidar-Person O, Weltens CG, Fortpied C, Scheijmans LJEE, Kirkove CY, Budach V, Peignaux-Casasnovas K, Valli M, Peters M, van der Leij F, Rivera S, Weidner N, van den Bongard DHJG, Linsenmeier C, Abdah-Bortnyak R, Hosni S, Koiter E, Engelen AM, Baten A, Champezou L, Fourquet A, Bartelink HGMM, Struikmans H, Poortmans PMP, EORTC Radiation Oncology and Breast Cancer Groups
doi: 10.1016/S1470-2045(26)00233-0
Breast Cancer
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
Clin Cancer Res
Jhaveri K, Eli LD, Hurvitz SA, Brufsky A, Bose R, de Miguel M, Unni N, Reid S, Quinn DI, Mahalingam D, Saura Manich C, García-Sáenz JÁ, Martínez-Bueno A, Guerrero-Zotano A, Trédan O, Wildiers H, Bischof GF, Bebchuk J, Solit DB
doi: 10.1158/1078-0432.CCR-25-4135
Breast Cancer
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer
Clin Cancer Res
Dieci MV, Gasparini E, Nicolè L, Schmid P, Zambelli A, Favaretto A, Piacentini F, Bianchi GV, Mion M, Ferro A, Arpino G, Emiliani A, Cinieri S, Zamagni C, Gennari A, Spazzapan S, Sartori D, Zustovich F, Tamberi S, Del Mastro L, De Laurentiis M, Musolino A, Cagossi K, Generali D, Giarratano T, Giovanardi F, De Salvo GL, Conte P, Guarneri V
doi: 10.1158/1078-0432.CCR-26-0975
Breast Cancer
Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial
JAMA Oncol
Karsten MM, Gebert P, Pross T, Hage AM, Dordevic AD, Stephan S, Kühn F, Doppelbauer L, Blohmer JU, Fischer F, Rose M, Pöhlmann A, Materne B, Petersen MA, Pauler L, Ferencz J, Wesselmann S, Breidenbach C, Grittner U, Kowalski C
doi: 10.1001/jamaoncol.2026.2661